Mirxes Holding Co., Ltd. operates as an investment holding company. The company employs 347 full-time employees The company went IPO on 2025-05-23. The company develops and commercializes accurate, non-invasive, and affordable blood-based miRNA test kit products for the early detection of cancer and other diseases. Its segments include Infectious diseases and Early detection and precision multi-omics. Its solutions include cancer screening; clinical sequencing; cancer treatment selection, and infectious diseases. Its core product (namely, GASTROClear), two other commercialized products (namely, LUNGClear and Fortitude), and six product candidates at pre-clinical stage. GASTROClear is a blood-based miRNA detection panel consisting of 12 miRNA biomarkers for gastric cancer screening. LUNGClear, its lung cancer screening product candidate, is a detection panel consisting of miRNA biomarkers discovered and verified in multi-center studies. The company offers complete COVID-19 testing solutions.
02629.HK stock price ended at $22.6 on 木曜日, after dropping 5.83%
On the latest trading day Feb 12, 2026, the stock price of 02629.HK fell by 5.83%, dropping from $24.00 to $22.60. During the session, the stock saw a volatility of 8.94%, with prices oscillating between a daily low of $22.38 and a high of $24.38. On the latest trading day, the trading volume for 02629.HK decreased by 1.8M shares, aligning with the declining prices, which may indicate weakening market confidence in the near term. In total, 3.8M shares were traded, with a market value of approximately $6.7B.